Until very recently, obesity was one of those issues we talked about in much the same way as climate change: everyone knows it is a disaster, everyone feels guilty about it, and yet nothing much changes at the core. The advice keeps repeating, diets follow diets, people lose weight and gain it back in a yo‑yo rhythm. Gyms fill up in January with “resolution‑makers” only to empty out again in February. It all looks a bit as if society were breathing: an inhale of hope, an exhale of resignation.
And then Mounjaro arrived. And with it, a strange silence. Not in the media. A biological one.

For the first time in modern history, we are not confronting obesity with moralizing or discipline, but with a technology that elegantly sidesteps the whole debate about willpower. Drugs in the GLP‑1 class do something disturbingly simple: they switch off hunger. Or more precisely, they rewrite its intensity. A person eats less not because they have stronger willpower, but because they simply no longer want more. No inner struggle, no bargaining, no late‑night voice scolding them for yet another secretly eaten chocolate bar.

What is striking is that this topic is nowhere near as prominent in the media as AI. Yet this is not a minor innovation, but a genuine paradigm shift.

Biology defeats character

For decades, we framed obesity as a personal failure disguised as statistics. Every chart doubled as a moral verdict. Fatness was not an illness but proof of weakness. GLP‑1 drugs shatter this story with the cold elegance of a lab experiment. They show that hunger is not an abstract notion, but a chemical signal – and that someone’s “gluttony” may simply be a differently wired brain.

At that moment, the entire cultural scaffolding collapses. If obesity is a biological condition, shame stops making sense. Heroism stops making sense. And above all, a vast industry built on people failing so that they can try again stops working. When food stops screaming, there is nothing left to silence.

An economy after the injection

It is no coincidence that obesity has suddenly begun to appear in economic analyses. Consultants at McKinsey & Company speak of GLP‑1 drugs as a “game changer”, and they do not mean healthcare. They mean a world in which millions of people eat less. And differently. And with far less emotional investment.

This is an economic shock comparable to the arrival of the internet, only in the opposite direction. Not more consumption, but less. Not hunger for products, but its quiet extinction. The food industry, fast food chains, manufacturers of sweets and “functional snacks” now face a technology that does not compete with advertising, but with chemistry. And chemistry, as we know, has the final word inside the human body.

At the same time, the other side of the equation opens up. Less obesity means less diabetes, fewer heart attacks, lower costs of chronic care. In the long run, health systems might for the first time in history genuinely save money. The question is: who will pay for the transition, and who will be entitled to benefit from it?

Czech reality: a rationed revolution

In the Czech context, this global revolution takes a very down‑to‑earth form. The drugs exist, doctors know about them, patients want them – but the system hesitates. Health insurers look at the price, not at what will happen over a ten‑year horizon. Obesity may be officially classified as a disease, but it still carries a tinge of suspicion. As if you were expected to first “live it through” before you deserve modern treatment.

The result is a peculiar transitional phase. Those who have money are losing weight quietly and quickly. For illustration, the more expensive drugs like Mounjaro can cost a Czech patient around 6,000 crowns for a lower dose and around 12,000 crowns for a higher one. Those who do not have the money watch the miracle unfold on Instagram and in the waiting rooms of private clinics. If this gap is not solved at the systemic level, a new form of inequality will soon emerge: slimness as a privilege, and obesity as the stigma of poverty.

It is a paradox. Drugs that dissolve shame can, at the same time, recreate it – only distributed along new lines.

Čtěte také www.solvo.institute/blog

A world without comfort

Perhaps the least explored impact of the GLP‑1 revolution has nothing to do with the body, but with meaning. Food has always been more than calories. It has been reward, ritual, an anaesthetic against anxiety. When this mechanism weakens, not only the kilos disappear. One of the most accessible forms of comfort disappears with them.

People on these drugs often describe a strange calm. Food stops exciting them and, more importantly, it stops structuring their day. With that calm comes a question we have not had to ask for a long time: what exactly are we dealing with when we are not eating? What emotions remain when they can no longer be washed down or eaten away?

In this sense, this is not just about pharmacology but about anthropology. About rewriting our relationship to the body, to control and to pleasure. And perhaps also about a quiet admission that many of our “weaknesses” were not moral, but neurochemical.

So does the end of obesity also mean the end of our illusions?

Mounjaro and similar drugs will not abolish obesity. But they will abolish many of the lies we have told ourselves about it: about willpower, about laziness, about character. And at the same time, they will open up new, much less comfortable questions. What will a society do that has lost its hunger but not its emptiness? What will an economy do that was built on surplus? And what will we do when we realize that technology can “fix” even those parts of ourselves we once regarded as the very core of our identity?

Perhaps the biggest change is not in people’s bodies, but in the fact that, for the first time, we are looking at obesity without a moralizing filter. And that is a revolution that hurts more than the injection itself.